Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 339-354 , October 2004

Pharmacotherapy for excessive daytime sleepiness

  • Dev Banerjee

      Affiliations

    • Sleep and Ventilation Unit, Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
    • Sleep Research Group, Woolcock Institute of Medical Research, Royal Prince Alfred Hospital and University of Sydney, Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    • ,
  • Michael V. Vitiello

      Affiliations

    • Psychiatry and Behavioral Sciences, University of Washington, 98195-6560 Seattle, WA, USA
    • ,
  • Ronald R. Grunstein

      Affiliations

    • Sleep Research Group, Woolcock Institute of Medical Research, Royal Prince Alfred Hospital and University of Sydney, Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-2-95158630; fax: +61-2-95158196

References 

  1. Roth T, Roehrs TA. Etiologies and sequelae of excessive daytime sleepiness. Clin Ther. 1996;18:562–576
  2. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  3. Happe S. Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs. 2004;63:2725–2737
  4. Mitler MM. Evaluation of treatment with stimulants in narcolepsy. Sleep. 1994;17:S103–S106
  5. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience. 2000;99:651–659
  6. Porkka-Heiskanen T. Adenosine in sleep and wakefulness. Ann Med. 1999;31:125–129
  7. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res—Brain Res Rev. 1992;17:139–170
  8. Materi LM, Rasmusson DD, Semba K. Inhibition of synaptically evoked cortical acetylcholine release by adenosine: an in vivo microdialysis study in the rat. Neuroscience. 2000;97:219–226
  9. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett. 1991;123:20–22
  10. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591:319–326
  11. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21:1787–1794
  12. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003;339:143–146
  13. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997;42:1181–1183
  14. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett. 1998;253:135–138
  15. Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology. 2000;39:1974–1983
  16. Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res. 2002;68:107–112
  17. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA. 1996;93:14128–14133
  18. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998;241:95–98
  19. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the wake-promotingagent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: anin vitro pharmacologic study. Sleep. 2004;27:19–25
  20. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  21. Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev. 2000;4:57–99
  22. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75:711–721
  23. Nishino S, Mignot E. Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations. Clin Pharmacokinet. 1999;37:305–330
  24. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol. 2002;40:1243–1255
  25. Mandal HG. Update on caffeine consumption, disposition and action. Food Chem Toxicol. 2002;40:1231–1234
  26. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ. 1999;148:173–195
  27. Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38:971–978
  28. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38:276–282
  29. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol. 1999;39:281–288
  30. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39:30–40
  31. Hellriegel ET, Arora S, Nelson M, Robertson P. Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J Clin Pharmacol. 2001;41:895–904
  32. Hellriegel ET, Arora S, Nelson M, Robertson P. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol. 2002;42:448–458
  33. Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos. 2000;28:664–671
  34. Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther. 2002;71:46–56
  35. Circa Pharmaceuticals, Inc. . Provigil (Modafinil) patient information. Copiague, NY. 1997;
  36. Newhouse PA, Belenky G, Thomas M, Thorne D, Sing HC, Fertig J. The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacology. 1989;2:153–164
  37. Waters WF, Magill RA, Bray GA, Volaufova J, Smith SR, Lieberman HR, et al. A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation. Nutr Neurosci. 2003;6:221–235
  38. Wiegmann DA, Stanny RR, McKay DL, Neri DF, McCardie AH. Methamphetamine effects on cognitive processing during extended wakefulness. Int J Aviat Psycho. 1996;6:379–397
  39. Beaumont M, Batejat D, Pierard C, Coste O, Doireau P, Van Beers P, et al. Slow release caffeine and prolonged (64-h) continuous wakefulness: effects on vigilance and cognitive performance. J Sleep Res. 2001;10:265–276
  40. Patat A, Rosenzweig P, Enslen M, Trocherie S, Miget N, Bozon MC, et al. Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep-deprived subjects. Hum Psychopharmacol. 2000;15:153–170
  41. Brice C, Smith A. The effects of caffeine on simulated driving, subjective alertness and sustained attention. Hum Psychopharmacol. 2001;16:523–531
  42. De Valck E, Cluydts R. Slow-release caffeine as a countermeasure to driver sleepiness induced by partial sleep deprivation. J Sleep Res. 2001;10:203–209
  43. Van Dongen HP, Price NJ, Mullington JM, Szuba MP, Kapoor SC, Dinges DF. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep. 2001;24:813–819
  44. Lagarde D, Batejat D, Sicard B, Trocherie S, Chassard D, Enslen M, et al. Slow-release caffeine: a new response to the effects of a limited sleep deprivation. Sleep. 2000;23:651–661
  45. Sicard BA, Perault MC, Enslen M, Chauffard F, Vandel B, Tachon P. The effects of 600 mg of slow release caffeine on mood and alertness. Aviat Space Environ Med. 1996;67:859–862
  46. Lagarde D, Batejat D, Van Beers P, Sarafian D, Pradella S. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol. 1995;9:271–279
  47. Pigeau R, Naitoh P, Buguet A, McCann C, Baranski J, Taylor M, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res. 1995;4:212–228
  48. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology. 2002;159:238–247
  49. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003;165:260–269
  50. Randall DC, Shneerson JM, Plaha KK, File SE. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol. 2003;18:163–173
  51. Caldwell JA, Smythe NK, Leduc PA, Caldwell JL. Efficacy of Dexedrine for maintaining aviator performance during 64 hours of sustained wakefulness: a simulator study. Aviat Space Environ Med. 2000;71:7–18
  52. Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Sea-Air-Land. Psychopharmacology. 2002;164:250–261
  53. Tharion WJ, Shukitt-Hale B, Lieberman HR. Caffeine effects on marksmanship during high-stress military training with 72 hour sleep deprivation. Aviat Space Environ Med. 2003;74:309–314
  54. Horne JA, Reyner LA. Counteracting driver sleepiness: effects of napping, caffeine, and placebo. Psychophysiology. 1996;33:306–309
  55. Reyner LA, Horne JA. Early morning driver sleepiness: effectiveness of 200 mg caffeine. Psychophysiology. 2000;37:251–256
  56. Buguet A, Moroz DE, Radomski MW. Modafinil-medical considerations for use in sustained operations. Aviat Space Environ Med. 2003;74:659–663
  57. Caldwell JA, Caldwell JL, Smythe NK, Hall KK. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology. 2000;150:272–282
  58. Chapotot F, Pigeau R, Canini F, Bourdon L, Buguet A. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology. 2003;166:127–138
  59. Roehrs T, Papineau K, Rosenthal L, Roth T. Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharmacol. 1999;7:145–150
  60. Zwyghuizen-Doorenbos A, Roehrs TA, Lipschutz L, Timms V, Roth T. Effects of caffeine on alertness. Psychopharmacology. 1990;100:36–39
  61. Kelly TL, Mitler MM, Bonnet MH. Sleep latency measures of caffeine effects during sleep deprivation. Electroencephalogr Clin Neurophysiol. 1997;102:397–400
  62. Shilo L, Sabbah H, Hadari R, Kovatz S, Weinberg U, Dolev S, et al. The effects of coffee consumption on sleep and melatonin secretion. Sleep Med. 2002;3:271–273
  63. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj MJ. Differential effects of a new central adrenergic agonist modafinil and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res. 1989;9:183–195
  64. Buguet A, Montmayeur A, Pigeau R, Naitoh P. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects on two nights of recovery sleep. J Sleep Res. 1995;4:229–241
  65. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med. 2001;2:5–17
  66. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol. 2003;53:154–166
  67. Marotta PJ, Roberts EA. Pemoline hepatotoxicity in children. J Pediatr. 1998;132:894–897
  68. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam. 2003;20:1–30
  69. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med. 2000;1:231–243
  70. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000;1:109–116
  71. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am, J Resp Crit Care Med. 2001;164:1675–1681
  72. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep. 2001;24:385–391
  73. Fry JM. Treatment modalities for narcolepsy. Neurology. 1998;50:S43–S48
  74. Daly D, Yoss RE. The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report. Mayo Clin Proc. 1956;31:620–625
  75. Yoss RE, Daly D. Treatment of narcolepsy with ritalin. Neurology. 1959;9:171–173
  76. Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep. 1993;16:306–317
  77. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7:93–118
  78. Mitler MM, Walsleben J, Sangal RB, Hirshkowitz M. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalogr Clin Neurophysiol. 1998;107:33–38
  79. US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43:88–97
  80. US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54:1166–1175
  81. Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17:S107–S112
  82. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444–451
  83. Besset A, Chetrit M, Carlander B, Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin. 1996;26:60–66
  84. Schwarz S, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26:252–257
  85. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Saf. 2002;25:791–809
  86. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep. 1997;20:28–33
  87. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000;14:53–60
  88. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol. 2000;23:149–156
  89. Guilleminault C, Aftab FA, Karadeniz D, Philip P, Leger D. Problems associated with switch to modafinil—a novel alerting agent in narcolepsy. Eur J Neurol. 2000;7:381–384
  90. Thorpy MJ, Schwartz JR, Kovacevic-Ristanovic R, Hayduk R. Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Psychopharmacology. 2003;167:380–385
  91. Schwartz JR, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med. 2003;4:43–49
  92. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev. 2001;5:349–358
  93. Montplaisir J, Fantini L. Idiopathic hypersomnia: a diagnostic dilemma. A commentary of idiopathic hypersomnia (Billiard M., Dauvilliers Y.). Sleep Med Rev. 2001;5:361–362
  94. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:695–700
  95. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997;120:1423–1435
  96. Guilleminault C, Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep. 1996;19:S117–S122
  97. Bedard MA, Montplaisir J, Malo J, Richer F, Rouleau I. Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airways pressure (CPAP). J Clin Exp Neuropsychol. 1993;15:330–341
  98. Sforza E, Krieger J. Daytime sleepiness after long-term continuous positive airway pressure (CPAP) treatment in obstructive sleep apnea syndrome. J Neurol Sci. 1992;110:21–26
  99. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Resp Crit Care Med. 2001;163:918–923
  100. Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest. 2003;124:2192–2199
  101. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med. 2003;4:393–402
  102. Pollak CP. Con: modafinil has no role in management of sleep apnea. Am J Resp Crit Care Med. 2003;167:106–107
  103. Black J. Pro: modafinil has a role in management of sleep apnea. Am J Resp Crit Care Med. 2003;167:105–106
  104. Pack AI. Should a pharmaceutical be approved for the broad indication of excessive sleepiness?. Am J Resp Crit Care Med. 2003;167:109–111
  105. Hart CL, Ward AS, Haney J, Nasser J, Foltin RW. Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work. Psychopharmacology. 2003;169:42–51
  106. Muehlbach MJ, Walsh JK. The effects of caffeine on simulated night-shift work and subsequent daytime sleep. Sleep. 1995;18:22–29
  107. Hughes RJ, Van Dongen H, Dinges DF, Rogers N, Wright KP, Edgar DF, et al. Modafinil improves alertness and performance during simultated night work. Sleep. 2001;24(suppl 1):A200
  108. Schweitzer PK, Kader GA, Walsh JK. Modafinil enhances alertness and performance during four consecutive stimulated night shifts. Sleep. 2002;25(suppl 1):A158
  109. Dinges DF, Wright KP, Walsh JK, Roth T, Black J, Czeisler CA. Modafinil improves psychomotor vigilance performance in shift work sleep disorder. Sleep. 2003;26(suppl 1):A87
  110. Czeisler CA, Dinges DF, Walsh JK, Roth T, Niebler G. Modafinil for the treatment of excessive sleepiness in chronic shift work sleep disorder. Sleep. 2003;26(suppl 1):A114
  111. Rosenberg R, Erman M, Emsellem HA, Niebler G, Wyatt-Knowles E. Modafinil improves quality of life and is well tolerated in shift work sleep disorder. Sleep. 2003;26(suppl 1):A112

PII: S1087-0792(04)00024-3

doi: 10.1016/j.smrv.2004.03.002

Sleep Medicine Reviews
Volume 8, Issue 5 , Pages 339-354 , October 2004

Article Tools